The goal of this study was to develop a small, stable liposomal carrier for antisense oligodeoxynucleotides (asODN) that would have high trapping efficiencies and long circulation times in vivo. Traditional cationic liposomes aggregate to large complexes and, when injected intravenously, rapidly accumulate in the liver and lung. We produced charge-neutralized liposome-asODN particles by optimizing the charge interaction between a cationic lipid and negatively charged asODN, followed by a procedure in which a layer of neutral lipids coated the exterior of the cationic lipid-asODN particle. The coated cationic liposomes had an average diameter of 188 nm and entrapped 85-95% of the asODN. The biodistribution and pharmacokinetics of an 18-mer 125 I-labeled phosphorothioate ODN formulated by this method were determined after tail vein injection in mice. The majority of the asODN was cleared from blood, with a half-life of Ͼ10 hours compared with Ͻ1 hour for free asODN. When coupled with an anti-CD19 targeted antibody, this formulation was also effective at delivering an MDR1 asODN to a multidrug-resistant human B-lymphoma cell line in vitro, decreasing the activity of P-glycoprotein. No inhibition was found for nontargeted formulations or for free asODN. A number of therapeutic opportunities exist for the use of small, stable, long-circulating, and targetable liposomal carriers such as this, with high trapping efficiencies for asODN. Cancer Gene Therapy (2000) 7, 466 -475
A ntisense oligodeoxynucleotides (asODN) comprise a group of therapeutic agents specific for the treatment of diseases that occur as the result of the overexpression of a normal gene, the expression of a mutant gene, or the presence of an infectious agent. Several oncogenes or cancer-related genes have been examined as potential targets for modulation by asODN (reviewed in Ref. 1) . Down-regulation of gene expression has been demonstrated in many in vitro systems (reviewed in Ref. 2) , and there are also published reports of asODN inhibition of target gene expression in animal models of cancer, [3] [4] [5] cardiovascular disease, 6 and several central nervous system applications. [7] [8] [9] There are currently at least 12 clinical trials using asODN to treat diseases such as Crohn's disease and non-Hodgkin's lymphoma, as well as viral infections such as human immunodeficiency virus and cytomegalovirus. 10 Throughout this period of development, liposomes have played an important role as carriers for asODN.
In vitro, cationic liposomes have been shown to dramatically enhance the uptake and pharmacological activity of asODN, and in some instances, cationic liposomes may be absolutely necessary for the activity of asODN. 11 Commonly used formulations consist of cationic lipids mixed in approximately equimolar concentrations with the helper lipid dioleoylphosphatidylethanolamine (DOPE), similar to the transfection complexes used to deliver plasmid DNA. 12, 13 Preformed cationic liposomes are mixed with asODN, and cationic lipid-asODN complexes are formed through the electrostatic interactions. These complexes are very effective at entrapping asODN and mediating their delivery to cells in vitro.
In vivo, the requirement for a lipid carrier is much less clear. Several examples of the therapeutic activity of asODN in animal models as well as clinical trials in humans exist, and in these examples lipid carriers have not been used. However, free asODN are rapidly cleared from circulation, and improvements in the pharmacokinetics and specific activity of asODN may be possible with the use of a well-designed lipid carrier. Understand-ing the pharmacokinetics and biodistribution of liposomal asODN is an important prelude to designing appropriate clinical applications. Two previous studies on the biodistribution of cationic liposomal phosphorothioate asODN complexes found that, immediately after intravenous (i.v.) injection, the complexes accumulated primarily in the lung and liver. 14, 15 The liposome formulations were similar to those used in vitro: a cationic lipid mixed with DOPE and then complexed with asODN. However, the relatively static environment of a tissue culture dish is quite unlike the in vivo environment; therefore, some effort should be made to optimize liposomal asODN carriers if they are to be used in vivo.
Past studies using liposomes as drug carriers in vivo have shown that liposomes must be able to avoid uptake into the liver and spleen to achieve passive or ligandmediated targeting. 16, 17 The extremely short circulation times of the cationic liposome-asODN complexes described previously would hinder targeting to diseased tissues in vivo. In addition, interaction of these complexes with serum proteins and nontarget cells as a result of the excess positive charge that these complexes carry would interfere with ligand-mediated targeting to a specific cell type.
In this study, our goal was to develop a liposomal carrier that would be efficient at entrapping asODN, be stable and of small (Ͻ200 nm) size, and be able to circulate in blood for extended periods after i.v. administration. A Bligh and Dyer 18 extraction procedure was used by Reimer et al 19 to evaluate the formation of hydrophobic complexes between cationic lipid and plasmid DNA. These complexes exist in an organic solvent (CHCl 3 ), and therefore will not be suitable for transfection; however, they may serve as useful intermediates in the formation of liposomal DNA carriers. 19 Because the complexes form as a result of the electrostatic interaction between the cationic lipid and the DNA, this procedure may also be used for the extraction of phosphorothioate asODN. We hypothesized that the hydrophobic cationic lipid-asODN particles could be coated with neutral phospholipids (PLs) and lipid derivatives of polyethylene glycol (PEG) through a reverse phase evaporation procedure similar to that described by Szoka and Papahadjopoulos. 20 Sequestration of positive charges in the liposome interior and the presence of PEG would prevent rapid removal of the resulting coated cationic liposomes (CCL) from circulation. Coupling lipids for the attachment of targeting ligands could also be added during the coating procedure.
We describe the physical parameters and the pharmacokinetics of an 125 I-labeled phosphorothioate asODN formulated into CCL. We also determined the activity of an MDR1 asODN formulated in CCL and targeted against MDR1-expressing human B-lymphoma cells by a monoclonal antibody (mAb), anti-CD19, which binds to an internalizing receptor, CD19. The activity of P-glycoprotein (P-gp) could be inhibited by the targeted formulations but not by nontargeted formulations or free asODN.
MATERIALS AND METHODS

Preparation of ODN
An 18-mer phosphorothioate asODN complementary to the region of the initiation codon of the MDR1 gene (5Ј-GTC-CCCTTCAAGATCCAT-3Ј) was synthesized by the University Core DNA Services Lab at the University of Calgary (Calgary, Alberta, Canada). As a sequence control, a sense phosphorothioate was also synthesized and had the sequence 5Ј-ATG-GATCTTGAAGGGG-AC-3Ј. These sequences were used in another study that demonstrated antisense inhibition of MDR1, 5 and several other studies have successfully targeted this region of the MDR1 mRNA (reviewed in Ref. 21) . To follow the distribution of asODN in vivo, the asODN was labeled with 125 I using Iodogen (Pierce, Rockford, Ill), similar to the method described by Piatyszek et al. 22 125 I (185 mBq) was purchased from Amersham (Oakville, Ontario, Canada). The specific activity of the 125 I-asODN was ϳ700 kBq/g, with Ͻ5% free 125 I as determined by thin layer chromatography on polyethyleneimine-cellulose TLC plates (J.T. Baker, Phillipsburg, NJ). The 125 I label is covalently attached at the C-5 position of cytidine bases. 22, 23 Passively entrapped liposomal asODN (PELA) Neutral PELA were prepared by simply hydrating a lipid film in a concentrated solution of asODN. Partially hydrogenated soy phosphatidylcholine, iodine number 40 (PC40), cholesterol (Chol) (Avanti Polar Lipids, Alabaster, Ala), and PEG 2000 distearoylphosphatidylethanolamine (PEG-DSPE) were mixed in chloroform at a molar ratio of 2:1:0.1. PC40 and PEG-DSPE were provided by Sequus Pharmaceuticals (Menlo Park, Calif). The mixture was then dried to a thin film by rotary evaporation, and traces of chloroform were removed under vacuum overnight. A solution of 1.7 mM asODN in N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES) buffer (25 mM HEPES, 140 mM NaCl, pH 7.4) was added to the lipid film to give a PL concentration of ϳ300 mM; the film was allowed to hydrate for 6 hours at room temperature. An equal volume of asODN solution was then added, and the tube was vortexed for ϳ1 minute. The mixture was diluted to 75 mM PL with HEPES buffer and sonicated for 2 minutes. This protocol is similar to the minimal volume entrapment method described by Thierry and Dritschilo. 24 The liposomes were then extruded under N 2 pressure through 200-nm Nuclepore polycarbonate filters (Fisher, Whitby, Ontario, Canada) in HEPES buffer according to Olson et al. 25 For experiments in which an aqueous space marker, with neutral charge, was used to follow liposomal distribution, 125 I-tyraminylinulin ( 125 I-TI) was prepared by the method described by Sommerman et al 26 and passively entrapped similar to the protocol described above. Liposomes were sized by dynamic light scattering using a Brookhaven BI90 particle sizer (Brookhaven Instruments, Holtsville, NY 
Preparation of CCL containing asODN
AsODN were complexed with cationic lipids and coated with neutral lipid in the following manner: 700 g (ϳ0.118 mol) of 18-mer asODN was diluted to 250 L in distilled-deionized water (ddH 2 O) including a trace of 125 I-labeled asODN. In a separate tube, 2 mol of 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) were diluted to 250 L in CHCl 3 and 510 L of MeOH was added. The asODN in ddH 2 O was then added to the CHCl 3 /MeOH mixture containing DOTAP and the sample was mixed to form a Bligh-Dyer monophase. 18 In some experiments, less asODN was added to 2 mol of DOTAP to alter the Ϯ charge ratio. After a 30-minute incubation at room temperature, 250 L of CHCl 3 was added, followed by 250 L of ddH 2 O. The tube was vortexed briefly, and subsequently centrifuged at 900 ϫ g for 7 minutes. The system then existed as a biphase; the upper, aqueous phase was removed, and the amount of asODN was determined either by radioactive counts or by measuring the absorbance at 260 nm. This procedure resulted in ϳ95% of the asODN being extracted into the organic phase when a 1:1 (Ϯ) charge ratio (DOTAP to asODN) was used. The use of a Bligh-Dyer monophase to extract plasmid DNA into an organic phase using cationic lipid has been reported previously.
19,27 PC40, Chol, and PEG-DSPE, all in CHCl 3 , were added to the organic phase to give a molar ratio of PC40 to Chol to DOTAP to PEG-DSPE of 3:2:1:0.2. ddH 2 O was added to give a PL concentration of 20 -30 mM (in ddH 2 O), and this mixture was vortexed and then sonicated for ϳ1 minute to form an emulsion. The organic phase was then evaporated by rotary evaporation at ϳ500 mm Hg. The system formed a gel phase after evaporation of most of the organic phase; after further evaporation (sometimes with slight agitation), the system reverted into the aqueous phase, which was briefly vortexed, and residual CHCl 3 was evaporated.
The vesicles formed by this procedure had diameters in the range of 600 -800 nm. They were subsequently extruded through 400-and then 200-nm polycarbonate filters. Liposomes were sized by dynamic light scattering using a Brookhaven BI90 particle sizer (Brookhaven Instruments). Free asODN (if any) was separated from lipid-associated asODN by filtration down a Sepharose CL-4B column equilibrated with HEPES buffer (25 mM HEPES, 140 mM NaCl, pH 7.4).
To produce antibody (Ab)-targeted CCL, the coupling lipid 4-(p-maleimidophenyl) butyrate-PEG-DSPE (custom synthesized by Shearwater Polymers. Huntsville, Ala) was included at 0.5 mol% total lipid. The final lipid composition was 2:1:0.06: 0.015 (PC40 to DOTAP to PEG-DSPE to 4-(p-maleimidophenyl) butyrate-PEG-DSPE). After extrusion in ddH 2 0, samples were dialyzed against at least 100 volumes of HEPES buffer for 1 hour. Anti-CD19 mouse mAb from mouse ascites, produced by the FMC-63 hybridoma cell line (provided by Dr. H. Zola, Children's Health Research Institute, Adelaide, Australia 28 ), was purified on a protein G column (HiTrap Protein G, Pharmacia). A solution of 10 mg/mL Ab in HEPES buffer (25 mM HEPES, 140 mM NaCl, pH 8.0) was thiolated using Traut's reagent (2-iminothiolane) (Sigma, Oakville, Ontario, Canada) at a 15:1 molar ratio of Traut's:Ab for 1 hour at room temperature. After incubation, free Traut's was removed by separation on a Sephadex G-50 spin column (Pharmacia, Uppsala, Sweden) and thiolated Ab was added to CCL at a lipid to Ab molar ratio of 1000:1. The coupling reaction was carried out overnight at room temperature, and noncoupled Ab was separated from CCL on the following day by passage down a Sepharose CL-4B column. Coupling efficiency ranged from 50% to 80%, resulting in 0.5-0.8 nmol Ab per mol lipid (78 -125 g Ab per mol lipid).
Animal experiments
Female CD 1 /ICR outbred mice (6 -8 weeks old) were purchased from Charles River (Montreal, Quebec, Canada) and used within 5 weeks of delivery, at which time their weight ranged from 24 to 30 g. Mice were given a single bolus injection via the tail vein of free or liposomal asODN in a total volume of 0.2 mL. Radioactive counts ( 125 I-TI or 125 I-asODN) for each injection ranged from 0.4 to 2 ϫ 10 5 cpm. Mice (three per group) were sacrificed at specific timepoints (0.25, 0.5, 1, 4, 12, and 24 hours), organs were dissected and weighed, and radioactive counts were determined in a Beckman gamma 8000 counter (Mississauga, Ontario, Canada). Liver, spleen, lung, heart, kidney, thyroid, and 100 L of blood were dissected and counted, and the remainder of the animal (carcass) was also counted. The radioactive counts in each tissue and the carcass were corrected using blood correction factors, which were determined previously. 29 In experiments in which 125 I-TI was used as an aqueous space liposomal marker, data are presented as a percentage of in vivo counts per minute. This value is calculated as the counts per minute in blood as a percentage of the total counts per minute left in the body at that timepoint, and corrects for leakage of the label and represents intact liposomes remaining in the body at given timepoints. 30 Pharmacokinetic parameters were calculated using pK Analyst version 1.0 software (Micromath Scientific Software, Salt Lake City, Utah).
Down-regulation of P-gp activity
For the evaluation of the antisense activity of the CCL formulation, we used a multidrug-resistant clone (Namalwa/ MDR 40 ) of the human B-lymphoma cell line (Namalwa), which was produced by transfection with a plasmid containing the MDR1 gene (pHAMDR/A, kindly provided by M. Gottesman, National Cancer Institute, Bethesda, Md) and then selected in increasing concentrations of vincristine up to 40 ng/mL. Namalwa/MDR 40 are ϳ20-fold more resistant to doxorubicin than are Namalwa/parent cells, and they stain positive for P-gp by flow cytometry using an anti-P-gp Ab (data not shown). For antisense experiments, cells were incubated for 1 hour per day for 3 days with 0.7 M MDR1 asODN or sense ODN (sODN) formulated in anti-CD19-targeted CCL, nontargeted CCL or LipofectAMINE (Life Technologies, Burlington, Ontario, Canada), and 1 M or 13 M free asODN or sODN. Cell concentrations were measured daily using a Coulter counter (Coulter, Hialeah, Fla), and no inhibition of cell growth was observed from the different liposomal or free antisense treatments. Three days of antisense treatment should allow for a significant reduction in P-gp levels if translation is inhibited, because the metabolic half-life (t 1/2 ) of P-gp has been reported to range from 14 to 18 hours in different cell lines. 31, 32 We used a functional assay to evaluate the level of expression of P-gp. Calcein-acetoxymethylester (calcein-AM) (Molecular Probes, Eugene, Ore) is a lipid-soluble fluorogenic dye that has been shown to be a substrate for P-gp. 33 In non-P-gpexpressing cells, calcein-AM easily penetrates the cell membrane; once inside the cell, esterases cleave the ester bond, releasing calcein, which is hydrophilic and highly fluorescent. In P-gp expressing cells, calcein-AM is rapidly extruded from the plasma membrane, resulting in a decrease in the accumulation of fluorescent calcein. Therefore, multidrug-resistant cells expressing P-gp will be less fluorescent than cells not expressing P-gp. Immediately after asODN/sODN treatment (1 hour per day for 3 days), cells from each group were seeded in a 96-well plate (five wells per group, 5 ϫ 10 5 cells/well) and incubated for 15 minutes at 37°C in the presence of 0.25 M calcein-AM. Cells were then rinsed three times in cold media containing sera, and the fluorescence in each well was determined using a Millipore Cytofluor 2300 plate reader (Bedford, Mass) with the appropriate excitation filter (485 nm) and emission filter (530 nm).
RESULTS
Effect of PEG on blood levels of cationic liposomes
It has been established that liposomes containing PEGmodified lipids (PEG-DSPE) demonstrate enhanced circulation time in blood compared with identical formulations lacking PEG. 34 -36 The purpose of the first set of experiments was to determine whether PEG grafted to the liposome surface would increase the circulation time of cationic liposomes without asODN. Figure 1 compares the blood levels of liposomes containing different amounts of cationic lipid with or without PEG-DSPE at 24 hours postinjection. The data in Figure 1 are presented as a percentage of in vivo counts in blood, rather than as a percentage of the injected dose in blood. When using a non-metabolizable, aqueous-space marker such as 125 I-TI, leakage from liposomes results in rapid elimination of 125 I-TI by the kidneys. Presenting data in this way accounts for leakage and represents intact liposomes circulating in the bloodstream, allowing for a more accurate determination of the pharmacokinetics. 37, 38 In the absence of PEG-DSPE, all liposomes were rapidly cleared from circulation, resulting in Ͻ5% of liposomes present in blood. For liposomes containing 50 mol% cationic lipid (a DOTAP to PC40 ratio of 1:1), inclusion of PEG-DSPE did not increase the blood levels of liposomes. However, when the cationic lipid was reduced to 20 mol%, inclusion of 5 mol% PEG-DSPE significantly increased the blood levels of liposomes. At Յ10 mol% cationic lipid, PEG-DSPE had its maximum protective effect on circulation times; there was no significant difference between blood levels of PEG-containing liposomes at 0, 5, and 10 mol% cationic lipid. These results indicate that PEG-DSPE can increase the circulation times of liposomes containing DOTAP, particularly when Յ20 mol% DOTAP is used. Therefore, 5 mol% PEG-DSPE was added to the liposomal formulations in the subsequent experiments, which examined the pharmacokinetics of cationic liposomal asODN.
Characterization of liposomal asODN
After extrusion through 200-nm polycarbonate filters, the neutral liposomes had an average diameter of 197 Ϯ 2 nm (polydispersity 0.032 Ϯ 0.012), whereas the CCL had an average diameter of 188 Ϯ 1 nm (polydispersity 0.138 Ϯ 0.018). The size was stable in buffer at 4°C as well as in 25% fetal bovine serum at 37°C for at least 3 STUART, KAO, ALLEN: TARGETED LIPOSOMAL asODN FORMULATION days (data not shown). Entrapment of asODN within neutral liposomes resulted in ϳ20% of the added asODN associated with the lipid fraction after separation down a CL-4B column (Fig 2) . In contrast, all of the asODN remained associated with the lipid fraction when asODN were prepared by the CCL method (Fig 2) . Figure 3 shows the clearance from blood of both free and liposomal 125 I-labeled asODN injected into the tail vein of mice. Free asODN is rapidly cleared so that Ͻ10% of the injected dose remains in blood at 30 minutes postinjection. At this time, ϳ40% of the injected dose has already been eliminated from the body, possibly through the kidneys. 39 Most of the remaining radioactive counts existed in the carcass (undissected tissues including the bladder), liver, and kidney (Fig 4a) . At 24 hours postinjection, only 8% of the injected dose remained in vivo.
Pharmacokinetics of liposomal ODN
125 I-labeled asODN encapsulated within PC40:Chol: PEG-DSPE (PELA) liposomes demonstrate a much different blood profile. PELA had an initial phase of rapid clearance that accounted for only 10% of the injected dose (Fig 3) . The remainder was cleared with a t 1/2 of ϳ12 hours, and almost 20% of the injected dose remained in blood at 24 hours postinjection. The asODN distributed primarily into the liver and spleen at all timepoints, and carcass levels appear to increase at later timepoints (Fig 4b) . At 24 hours postinjection, ϳ45% of the injected dose remained in vivo.
125 I-labeled asODN entrapped within CCL displayed a profile that was similar to PELA; however, the initial clearance phase accounted for ϳ30% of the injected dose (Fig 3) . This is a result of increased uptake into the liver and spleen of a portion of the CCL dose (Fig 4c) . This may be a consequence of some exposure of cationic lipids at the liposomal surface resulting in opsonization, with subsequent removal by cells of the mononuclear phagocyte system (MPS). The remaining dose had clearance kinetics that were similar to the asODN entrapped within PELA; at 24 hours postinjection, Ͼ10% of the injected dose remained in the blood, and 37% remained in vivo. As with PELA, there was an increase in carcass levels over time, which could have resulted from the distribution of free asODN to carcass and/or from the accumulation of liposomal asODN in carcass. Table 1 gives the pharmacokinetic parameters for each treatment in our experiments. Encapsulation within liposomes resulted in increased mean residence times, decreased clearance rates, and increased area under the time-concentration curve (AUC) for the asODN. In the first set of experiments, the injected dose was 30 g asODN/mouse, and the results demonstrate that liposome encapsulation resulted in substantial decreases in clearance rates and increases in mean residence time and AUC compared with free asODN. The volume of distribution (V D ) for both liposome treatments was ϳ2 mL, which is close to the blood volume of a 25-g mouse, whereas the free asODN had a V D that was ϳ6-fold higher, indicating that it was widely distributed within the tissues. Liposome entrapment also resulted in smaller elimination rate constants (K) and longer terminal elimination half-lives (t 1/2 ␤).
In the second set of experiments in Table 1 , doses were standardized to 0.5 mol PL/mouse. The rationale for standardizing the dose of PL is that the lipid dose may have effects on liposomal pharmacokinetics; so long as the entrapped drug ( 125 I-asODN) has a slow rate of leakage, the pharmacokinetics will be governed by the liposomal carrier. 38 In this case, the AUC for asODN entrapped within CCL is dramatically greater than for PELA, resulting from the increased loading efficiency. Therefore, the amount of asODN injected per mol of PL is much greater, leading to a larger AUC. This is in contrast to asODN doses standardized to 30 g asODN/ mouse, in which case the AUC for PELA is greater than that for asODN within CCL. The V D and K values are similar in both cases; however, the t 1/2 is slightly longer for PELA at a dose of 30 g asODN/mouse.
In preparing the asODN by the CCL procedure, we attempted to achieve charge neutrality between the cationic lipid and the anionic asODN. We hypothesized that neutralizing the DOTAP with asODN and then coating the hydrophobic particles with neutral lipid and PEG would mask the positive charge, leading to long circulation times upon i.v. injection. To test this hypothesis, we compared the RES uptake at 15 minutes postinjection of three different CCL preparations with different amounts of added asODN for the same amount of lipid. At a 1:1 charge ratio, ϳ95% of the asODN was extracted from the aqueous phase into the organic phase, and at this ratio, most of the positive and negative charges should be neutralized. After the addition of neutral lipid and liposome formation via the reverse evaporation vesicles procedure, all of the asODN remains associated with the lipid; therefore, we assume that the charge interaction is maintained. In this case, the asODN/PL ratio is 17.6 nmol/mol (1.1:1 Ϯ charge ratio), and 30.4% Ϯ 2.44 of the dose was taken up by the liver and spleen. However, when less asODN was associated with the CCL, so that the asODN/PL ratio was 7.5 nmol/mol (2.6:1 Ϯ charge ratio), 41.0% Ϯ 0.93 of the dose was taken up by the liver and spleen. When no asODN was added to the CCL ( 125 I-TI used as a marker), 49% Ϯ 5.05 of the dose was taken up by the liver and spleen in 15 minutes. Therefore, we observed significantly greater uptake into the MPS tissues with an increasing Ϯ charge ratio (P Ͻ .01, one-way analysis of variance), with a high degree of negative correlation between the asODN/PL ratio and the uptake into the MPS (r 2 ϭ 0.9998). These results suggest that a net positive charge on the liposomes leads to greater distribution to MPS tissues.
Effect of different formulations of asODN on P-gp activity
We tested the efficacy of different liposomal asODN formulations against a multidrug-resistant human B-lymphoma cell line (Namalwa/MDR 40 ) in vitro, using an asODN that is complementary to the MDR1 initiation codon. We coupled an anti-CD19 mAb, which recognizes an internalizing epitope on B cells, to the surface of CCL to test the efficacy of a targeted CCL formulation. Figure 5 illustrates the results for the calcein fluorescence assay of P-gp activity. Fluorescence values for each treatment group were normalized to the sODN control in each case. Treatment with Lipofectamine (asODN) (37%), CCL (asODN) (11%), and 10 M free asODN (15%) resulted in increases in fluorescence relative to their respective sODN controls; however, the increases were not statistically significant. In contrast, treatment with anti-CD19-CCL (asODN) resulted in significant (P Ͻ .01) increases (65%) in cellular fluorescence compared with the anti-CD19-CCL (sODN) control. These sequence-specific results suggest that the expression of P-gp is being inhibited at the translational level, resulting in a net decrease in P-gp activity; however, this possibility cannot be confirmed by the present data. We have also evaluated the sensitivity of cells to doxorubicin after antisense treatments (data not shown). The results do not indicate that any of the antisense treatments examined in the fluorescence assay (Fig 5) cause significant changes in the level of resistance. The modest increase in fluorescence does not translate into biologically significant changes in doxorubicin cytotoxicity.
DISCUSSION
This study examined the pharmacokinetics of asODN formulated in a novel liposomal carrier; this carrier is designed to have a high loading efficiency, to be of small size (Ͻ200 nm), and to be able to circulate in the bloodstream for extended times. Our results indicate that the formulation has long-circulating characteristics similar to asODN passively entrapped within noncationic liposomes. We have also demonstrated that this formulation is effective at delivering an asODN against MDR1 and decreasing the activity of the target protein in vitro when coupled with a mAb targeted to an internalizing receptor on human B cells.
AsODN have poor pharmacokinetics, which could prevent therapeutic concentrations from being reached in target tissues. When injected i.v., free asODN leave circulation rapidly and extravasate into tissues; next, a great proportion is excreted in the urine. Studies examining the biodistribution of phosphorothioate ODN demonstrate a wide variation in the actual pharmacokinetic values; however, they all indicate that asODN have a biphasic pattern of elimination from blood, consistent with our current results. 39, 40 The initial distribution phase has been reported to have a t 1/2 ranging from Ͻ1 minute to Ͼ30 minutes and then a longer elimination phase ranging from Ͻ1 hour to Ͼ40 hours. These studies and others demonstrate that the kidney and liver are the major organs of uptake, and that these are the major sites of metabolism of asODN. 39 -41 In a recent review, Tonkinson and Stein 41 suggest that the concentrations of phosphorothioate ODN reached in the sera of human patients during an infusion (0.32-0.97 M) during a phase I clinical trial would not be high enough to begin to detect clinical responses. 42 AsODN could benefit from the use of a long-circulating liposomal carrier in vivo for several reasons. Entrapment within liposomes could increase the distribution of asODN to target tissues and away from sites of metabolism and excretion. Phosphorothioate asODN are modified to resist degradation by nucleases through the replacement of a non-bridging oxygen atom to a sulfur atom in the phosphodiester bond. However, nuclease resistance is not absolute, and studies have shown that significant metabolism occurs. 14, 39 Liposomes could provide a means of nuclease protection in the circulation as well as in tissues. AsODN carry a strong negative charge and therefore do not readily interact with or cross cell membranes. Association with cationic lipids is one way to overcome this problem; however, the cellular association and uptake of asODN mediated by cationic lipids is not cell-specific.
The present study indicates that cationic lipids provide a means of achieving efficient loading of asODN into liposomes and are therefore a desirable component of liposomal asODN formulations. However, the positive charge should be neutralized by asODN or shielded by coating lipid to prevent interaction with nontarget cells or opsonization by serum proteins, which leads to removal by cells of the MPS. We have used a procedure in which cationic lipid-asODN particles are coated with neutral lipids and a PEG-modified lipid that will add stability and increase circulation time upon i.v. adminis- tration. In addition, coupling lipids can be added to the coating lipid and, after liposome formation, cell-specific targeting ligands can be attached onto the surface to produce a targeted carrier. We have used Chol and PC40 as helper lipids in our formulations, rather than DOPE, which has recently been shown to be unnecessary for in vivo transfection using plasmid DNA. 43, 44 These studies demonstrated that Chol was a much better helper lipid than DOPE when assessing the expression of a reporter gene after i.v. injection of plasmid DNA-cationic liposome complexes (lipoplexes). Both of the liposomal asODN formulations used in our experiments contained mPEG-DSPE at 5 mol%; past studies have shown that PEG-DSPE decreases uptake into the liver and spleen, thereby increasing the circulation time of liposomes in blood. 34 -36 In the study by Hong et al, 43 it was found that lipoplexes containing PEG-PE were active in transfecting cells in vivo, even after long-term storage.
There is a striking decrease in the rate of clearance of the 125 I-asODN within CCL compared with other studies following the pharmacokinetics of asODN complexed with cationic liposomes. Past studies have demonstrated that the asODN lipoplexes leave the blood rapidly, accumulating in the liver; 14 in one study, embolism was suggested to account for a transient accumulation in the lung. 15 Because cationic lipids have been shown to be toxic in vitro as well as in vivo, accumulation in these tissues could lead to problems, especially after repeat administration. 45, 46 In both of these studies, cationic lipoplexes were used with no attempt to modify the formulation for use in vivo.
Litzinger et al 15 examined the biodistribution after i.v. injection into mice of an 125 I-labeled 18-mer phosphorothioate oligonucleotide complexed at a 4:1 (Ϯ) charge ratio with cationic liposomes composed of DC-Chol and DOPE. The lipoplexes that formed had a size that was Ͼ1800 nm; after injection, they accumulated in the lung within 5 minutes, followed by a gradual redistribution to the liver that accounted for the greatest proportion of the injected dose at 5 hours postinjection. 15 The blood clearance profile was biphasic, with an initial t 1/2 of Ͻ5 minutes and a terminal t 1/2 of ϳ5-6 hours. This pattern of distribution resulted in Ͻ5% of the injected dose existing in the blood at 1 hour postinjection, and much less than 1% at 24 hours.
Bennett et al 14 examined the biodistribution of a 3 H-labeled phosphorothioate asODN formulated with cationic liposomes composed of 1,2-dimyristyloxypropyl-N,N-dimethyl-N-hydroxyethylammonium bromide and DOPE (1:1 molar ratio) at a charge ratio of 2.5:1 (Ϯ). Similar to the study by Litzinger et al, 15 the liver (ϳ70%) and lung (ϳ20%) contained the greatest proportion of the injected asODN at 1 hour postinjection. These studies used formulations that are optimized for the delivery of asODN to cells in vitro, and some considerations should be made in tailoring a liposome formulation for use in delivering asODN in vivo.
As described in Materials and Methods, an effort was made to titrate the amount of cationic lipid required to complex the asODN so that there was no excess positive charge. We hypothesized that neutralizing the positive charge with negatively charged asODN would ultimately lead to a decrease in interaction of the cationic lipid with serum proteins (opsonins), which could mediate the uptake of liposomes into MPS tissues. Our results indicate that if the balance of positive to negative charge is upset, such that there is more positive charge (DOTAP) in the formulation than negative charge (asODN), there is a significantly greater distribution to these MPS tissues. This interpretation is supported by a study that demonstrated the reversal of a net positive charge on cationic liposomes to net negative after incubation in sera, indicating extensive interaction with serum proteins. 47 Other studies indicate that higher concentrations of sera are required to inhibit the cellular interaction of cationic liposomes lacking asODN than are required to inhibit the interaction when asODN were present in the formulation. 15 Neutral liposomes containing passively entrapped 125 IasODN avoid uptake into MPS tissues to a greater extent than cationic liposomes. However, the major drawback to using neutral liposomes is the inefficient loading of asODN within the aqueous space. As Figure  2 illustrates, only ϳ20% of the added asODN remains associated with the 200-nm liposomes after separation down a CL-4B column, and this loading could be expected to decrease with decreasing vesicle diameter. This results in a loss of expensive asODN, or necessitates a time-consuming recovery step, which may prevent the use of this formulation at a clinical level. In addition, the low loading efficiency makes the dose of lipid per dose of asODN much greater.
In contrast, virtually 100% of the added asODN remains associated with liposomes containing DOTAP prepared by the extraction-reverse evaporation vesicles (REV) procedure. This illustrates one of the major advantages of cationic lipids in liposomal-asODN formulations: the electrostatic interaction results in very efficient loading. The other advantage, which is exploited in vitro, is that excess positive charge will facilitate the delivery of asODN through interaction with the negatively charged cell membrane. However, if the pharmacokinetics of cationic liposomes are to be controlled in vivo and tissues outside of the MPS are to be targeted, an excess positive charge will be an undesirable characteristic. 48 Therefore, if cationic liposomes are to be used to deliver asODN in vivo, some effort must be made to optimize the formulation so that it can reach the target tissue. We have demonstrated that when formulated in a charge-neutralized fashion, cationic liposomal-asODN complexes coated with neutral lipids can circulate in blood for extended times. This may result in the opportunity for passive targeting to solid tumors as seen with Stealth liposomal drugs such as doxorubicin. 49, 50 The ability of liposomes to maintain asODN in the bloodstream presents the opportunity for ligand-mediated targeting to hematological diseases, as recently demonstrated in our laboratory. 51 P-gp, which is often expressed by tumor cells after STUART, KAO, ALLEN: TARGETED LIPOSOMAL asODN FORMULATION treatment with chemotherapeutic agents, is one of the proteins responsible for the multidrug resistance (reviewed in Ref. 52) . The ability to inhibit the expression of this protein, or inhibit its activity, would increase the susceptibility of these cells to chemotherapeutic treatment. AsODN have been proposed as tools to inhibit the expression of P-gp; there are several examples of this inhibition in vitro (reviewed in Ref. 21 ) and at least one example in vivo. 5 Because P-gp functions as a pump, its expression can be evaluated quickly and easily using a fluorescent substrate such as calcein-AM, which has been used to evaluate P-gp activity. 33, 53 In a study comparing several different assays of P-gp, calcein-AM extrusion was found to be as reliable as immunological assays or drug sensitivity assessments in evaluating the drug resistance in several tumor cell lines. Our results indicate that liposomal MDR1 asODN formulated in CCL and stabilized by PEG-DSPE do not demonstrate significant activity against P-gp expression. However, the activity of this formulation improves substantially when a targeting ligand is used that delivers asODN into target cells via receptor-mediated endocytosis. In fact, this formulation appears to be more active than a commercial cationic liposome formulation, which is known to be a very efficient delivery vehicle for asODN in vitro. 54, 55 The added advantages of our CCL formulation are its demonstrated stability and long circulation times upon i.v. injection. Future studies will be undertaken to evaluate the efficacy of this formulation in an in vivo model.
